Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

While nonpharmacological treatment of migraine and tension headache has increasingly been demonstrated to be efficacious, relatively little attention has been focused upon treatment of the more severe cluster headache. This has particularly been the case for the type of cluster headache known as chronic cluster. The present case study focused upon the treatment of a 69-year-old male with a 37-year history of headache activity. The description of headache matched those criteria currently considered to be indicative of chronic cluster headache. Following 6 weeks of baseline, during which daily ratings of head pain and daily ingestion of "as needed" (PRN) pain medication were collected, a 7-week treatment phase was implemented. Treatment consisted of thermal biofeedback coupled with a spouse contingency program (i.e., directing the spouse to avoid consequating subject reports of head pain). During the treatment phase, a near-100% reduction in amount of weekly PRN pain medication ingested was noted, along with a decrease in self-reports of head pain. Both of these decreases were maintained at 1-month, 4-month, and 15-month follow-ups. Implications for treatment of chronic cluster headache were discussed.
 ...
PMID:Behavioral treatment of chronic cluster headache in a geriatric patient. 650 10

The reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine (dTpa) is intended for use as a booster dose in individuals aged > or =4 years. A single dose of dTpa elicited generally similar levels of antibodies against pertussis antigens (pertussis toxoid [PT], filamentous haemagglutinin [FHA] and pertactin [PRN]) as a similar monovalent pertussis booster vaccine (ap) in adolescents or adults, irrespective of their prevaccination serological status or vaccination history. Levels of antibodies directed against diphtheria toxoid were similar in recipients of dTpa or a licensed reduced-antigen combined diphtheria-tetanus booster vaccine (Td). However, levels of antitetanus antibodies were significantly higher in recipients of Td vaccines compared with those receiving dTpa. Similar serological response rates were observed for anti-PT, -FHA and -PRN between those receiving dTpa or ap and a similar high percentage of recipients of dTpa and the Td vaccines had seroprotective levels of antibodies against diphtheria and tetanus toxoid. The most frequently reported local adverse reactions following immunisation with dTpa included pain, redness and swelling; general symptoms included fatigue, headache and fever.
 ...
PMID:Reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine (Boostrix). 1282 63

As aluminium in vaccines has been associated with the incidence of local side effects occurring after vaccination, this observer-blind randomised clinical trial was designed to evaluate the effect of lowering the aluminium content of a combined reduced-antigen-content dTpa vaccine on immunogenicity and safety when administered to healthy adolescents aged 10-18 years. A total of 647 subjects were enrolled, 224 (35%) received a dTpa formulation with 0.5 mg aluminium, 209 (32%) a formulation with 0.3 mg aluminium and 214 (33%) a formulation with 0.133 mg aluminium. One month after boostering, all subjects were seroprotected against diphtheria and tetanus toxoids. All subjects were seropositive for anti-FHA and anti-PRN but 4% of the initially seronegatives in both reduced aluminium groups did not seroconvert for anti-PT. Booster responses did not differ significantly between groups for any antibody, but post booster vaccination anti-PT GMC's differed significantly between groups and decreased when vaccine aluminium content decreased. No clear difference between study groups in local or general side effects was demonstrated. The most frequently reported symptoms after vaccination were injection site pain (89.5-90.7%), fatigue (42.1-47.4%) and headache (41.1-45.1%). This study showed that the aluminium content has a specific influence on the immunogenicity of this dTpa vaccine.
 ...
PMID:Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. 1567 Aug 88